INOVIQ Ltd (ASX:IIQ)

Market Cap	44.09M
Revenue (ttm)	1.69M
Net Income (ttm)	-7.08M
Shares Out	111.63M
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,290
Average Volume	94,635
Open	0.3850
Previous Close	0.3850
Day's Range	0.3850 - 0.3950
52-Week Range	0.3450 - 0.6900
Beta	1.81
RSI	55.75
Earnings Date	Aug 27, 2025

About INOVIQ

INOVIQ Ltd engages in the developing and commercializing of diagnostic and exosome‐based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. Its cancer diagnostic pipeline includes internal and partnered diagnostic tests for improved screening, diagnosis, treatment selection and...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2016
• Employees: 15
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IIQ

Financial Performance

In 2024, INOVIQ's revenue was 1.56 million, an increase of 0.67% compared to the previous year's 1.55 million. Losses were -6.55 million, -26.92% less than in 2023.